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Longer life expectancy has led to an increase in the prevalence of age-related cognitive
decline and dementia worldwide. Due to the current lack of effective treatment for these
conditions, preventive strategies represent a research priority. A large body of evidence
suggests that nutrition is involved in the pathogenesis of age-related cognitive decline,
but also that it may play a critical role in slowing down its progression. At a population
level, healthy dietary patterns interventions, such as the Mediterranean and the MIND
diets, have been associated with improved cognitive performance and a decreased
risk of neurodegenerative disease development. In the era of evidence-based medicine
and patient-centered healthcare, personalized nutritional recommendations would offer
a considerable opportunity in preventing cognitive decline progression. N-of-1 clinical
trials have emerged as a fundamental design in evidence-based medicine. They consider
each individual as the only unit of observation and intervention. The aggregation of
series of N-of-1 clinical trials also enables population-level conclusions. This review
provides a general view of the current scientific evidence regarding nutrition and cognitive
decline, and critically states its limitations when translating results into the clinical practice.
Furthermore, we suggest methodological strategies to develop N-of-1 clinical trials
focused on nutrition and cognition in an older population. Finally, we evaluate the potential
challenges that researchers may face when performing studies in precision nutrition
and cognition.
Keywords: N-of-1, personalized nutrition, prevention, Alzheimer’s disease, multimodal interventions, cognition,
cognitive decline
INTRODUCTION
Population aging has led to a substantial increase in the worldwide prevalence of dementia (1).
Currently, around 50 million people live with this condition, a figure that is expected to triple
by 2050 (2). Dementia comprises a wide range of medical and neuropsychiatric disorders. It is
characterized by a progressive cognitive decline greater than expected in normal aging, strongly
affecting the individual’s daily living activities and quality of life (3). Alzheimer’s disease (AD) is the
most common cause of dementia, accounting for 50–70% of cases (2).
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To date, there is a lack of effective disease-modifying
therapies for dementia. Since prevention is always better than
cure, interventions designed to prevent or delay the onset of
dementia represent nowadays an immediate research priority
(2). Attention has focused on modifiable risk factors, including
obesity, hypertension, diabetes, and physical inactivity (2, 4).
Evidence supports the fact that management of these conditions
through lifestyle interventions, such as healthy diets and physical
activity, may benefit cognitive function and reduce dementia risk
and severity (5–8). Indeed, optimal nutrition is a key component
for healthy aging. Nutritional preventive interventions present
unique advantages in terms of costs, safety, and sustainability for
long-term use (9, 10).
Although there is extensive literature discussing nutritional
strategies for the prevention of dementia, current evidence
presents inconsistent results. The heterogeneity of dementia from
a clinical, pathophysiological, and genetic viewpoint suggests
that dietary interventions are not universally applicable, but
when tailored to individual circumstances and risk profiles
might be more effective (8, 11, 12). Recently, the concept of
precision medicine for the prevention and management of AD
has emerged in the scientific community as a new model for
obtaining solid evidence-based medicine (13). An approach
that requires accounting for the inter-individual variability in
treatment response.
The gold-standard study design for assessing the effectiveness
of an intervention are the population-based, parallel-group,
randomized-controlled trials (RCTs) (14). However, such
effectiveness is commonly assessed using the average treatment
effect or type of subgroup analysis, without effectively tackling
the individual particular characteristics that may modify
treatment response (15). In addition, conventional RCTs seek
a high homogeneity within the study population in order to
increase the likelihood of demonstrating a true association
between intervention exposure and outcomes. As a result of the
strict inclusion and exclusion criteria, there is a considerable lack
of representativeness of some groups of patients, including those
with comorbid conditions or receiving concurrent therapies
(16, 17). As a result, evidence from RCTs cannot always be
extrapolated in the case of individual treatment decisions (17).
In the age of patient-centered care, a patient-oriented research is
called for (18, 19).
N-of-1 trials are coming to light in the medical field to address
the question of inter-individual variability in treatment response,
and the lack of knowledge about treatment effects in patients
who are typically excluded in RCTs. An N-of-1 trial refers to
a randomized, multiple, crossover trial conducted in a single
patient, typically where two or more treatment alternatives are
compared to each other or to a control intervention (17, 20). It
is noteworthy to mention that the Oxford Center for Evidence-
Based Medicine 2011 Levels of Evidence has categorized N-of-
1 trials as “level 1” of evidence for assessing treatment efficacy
in individual patients (21). For the purpose of valid inference
in individual patients, however, in N-of-1 trials, more data
needs to be collected from the patient than in conventional
RCTs, which focus on between patients rather than within
patient variation.
N-of-1 trials are part of the single-case design family
(22), which were first carried out in 1945 (23). Since then,
they have been widely used in the study of rare diseases
(24), in some medical areas such as pain, rheumatism and
pediatric oncology (25–30), and in the psychology, social, and
educational sciences. A renewed interest in this design has
arisen combined with the emergence of precision medicine to
tackle inter-individual differences within treatment responses.
In parallel, the development of electronic health information
technology (e.g., mobile apps and fitness trackers) has facilitated
the implementation of tools to intensively follow-up study
participants collecting data in a systematic and detailed way (31).
Such information enables researchers to precisely determine the
effect of an intervention at an individual level (32). Moreover,
the development of analytical tools capable of processing all
the generated data makes N-of-1 studies a feasible and realistic
approach for future precision medicine. In addition, data
aggregation from series of N-of-1 trials also makes it possible to
estimate effects on a subpopulation that shares certain factors, or
even in the population at large (12, 33).
The holistic approach of N-of-1 studies would, therefore,
be useful to manage P4 medicine—predictive, preventive,
personalized, and participatory (Figure 1) (34–36). Firstly,
however, throughN-of-1 trials it is possible to obtain information
of both between- and within-subject variations on biomarkers,
which could play a key role in identifying those that are
truly predictive (35). Secondly, intensive data collection over
time enables the detection of deviations from the norm which
may signal disease onset (35). Thirdly, it is possible to stratify
treatments according to the combination of some patient features
(e.g., gender, age, culture, socioeconomic status, history of
diseases) and the molecular and general-omics profile, which is
the basis of personalized or precision medicine (37, 38). Finally,
in N-of-1 trials, patients are more likely to participate, as they
may directly benefit from the tailored treatment (35).
DEMENTIA PREVENTION THROUGH
NUTRITIONAL INTERVENTIONS
Alzheimer’s Dementia Continuum
Dementia is the clinically observable result of the accumulation of
structural and functional cerebral damage that has commenced
10–20 years prior to the appearance of the first symptoms
(39, 40). Whilst aging is the strongest risk factor, dementia
is not an inevitable consequence. Environmental factors
(e.g., biological, psychological, and lifestyle factors), genetic
susceptibility, and their interaction over the life span contribute
to the physiopathological processes and clinical manifestation of
dementia (19).
Preclinical pathological events of dementia include the
exacerbation of certain age-related processes, such as reduced
blood flow due to atherosclerosis, impaired insulin resistance,
oxidative stress injury, and widespread, chronic, low-grade
inflammation (41). In the preclinical stages of AD, there
is also an aberrant deposition of misfolded proteins, called
extracellular amyloid β plaques (Aβ) and intracellular tau-based
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FIGURE 1 | N-of-1 trials approach for P4 Medicine: Predictive, Preventive, Personalized, and Participatory. Icons made by Freepik from www.flaticon.com.
neurofibrillary tangles, which contribute to the pathogenesis
of brain atrophic lesions and, hence, cognitive deterioration
(Figure 2A) (40, 43).
Preclinical events are grouped under the term subjective
cognitive decline (SCD). SCD is considered the precursor to
mild cognitive impairment (MCI) and potentially the earliest
clinical sign of AD (44). SCD implies the subjective expression
and experience of daily forgetfulness whilst performance on
cognitive tests is normal (45, 46). Not every individual with
characteristics suggestive of SCD will necessarily progress to AD.
Nevertheless, recognition of the condition has critical clinical
implications not only for patients and their physicians, but also
for the identification of new target populations for clinical trials
in the prevention of AD (47) (Figure 2B). On the other hand,
MCI is considered a prodromal stage of AD although it does not
strictly imply progression to clinically defined dementia (48). Use
of the MCI category has been a matter of debate (9, 49) since it is
irregularly defined and some subtypes are more likely to progress
to dementia than others (50).
The mechanisms underlying the progress from preclinical AD
to the symptomatic or prodromal stage of MCI, and ultimately
AD dementia, are not clearly defined (51). In fact, in the
90+ Autopsy Study, nearly 50% of individuals aged 90 years
or older with dementia did not have enough neuropathology
in their brain to explain their cognitive symptoms (52). In
contrast, around 30% of those older adults without dementia
or cognitive impairment presented intermediate or high levels
of AD pathology (53). Therefore, AD risk factors might
contribute to the neuropathological process throughmechanisms
other than amyloid or tau (8). On the other hand, certain
compensatory factors (e.g., maintenance of cardiovascular health,
high educational level, social engagement) might capacitate
individuals to tolerate considerable amounts of AD pathology
without suffering a clear dementia syndrome, even in carriers of
susceptibility alleles of genes such as apolipoprotein E (APOE)
and the ε4 allele (19, 54).
Large individual differences in rates of age-related cognitive
decline exist (55, 56), reflecting the complex interactions between
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FIGURE 2 | Conceptual framework for the relevance of nutritional interventions directed at improving cognitive function or slowing down cognitive decline at
preclinical stages of AD. (A) Role of nutritional interventions in the interaction between preclinical events of AD and modifiable risk and protective factors of AD.
(B) Window of opportunity to study the effect of nutrition interventions in the AD continuum. Adapted from Ávila-Villanueva and Fernández-Blázquez (42).
cognitive performance and environmental and genetic factors
(57). Evidence from human neuroimaging studies advocate
that three mechanisms may partially mediate these differences:
reserve, maintenance and compensation (57). Reserve is
defined as the accumulation of neuronal resources during the
lifespan (e.g., white matter quality of a fiber tract, functional
connectivity), which help to mitigate neuronal decline caused
by aging or in age-related diseases (57). Maintenance is defined
as the preservation of brain resources via constant recovery and
repair. Its efficacy depends on the magnitude of decline and
the ability to repair (57). Finally, compensation represents the
deployment of brain resources in response to task demands (57).
Reserve, maintenance and compensation may act at the genetic,
cellular and systems levels and can be influenced by several
factors (57–67). Table 1 summarizes potential determinants
contributing to cognitive reserve or cognition maintenance.
These mechanisms can work simultaneously and interact
between them. As exemplified by Cabeza et al. (57), education
could augment cognitive reserve by increasing synaptic density,
but this could only ameliorate cognitive decline if new synapses
are well-maintained. Likewise, it is also necessary to deploy
these resources during task performance, that is, to engage in
compensation. These factors and its related mechanisms could
explain the observed inter-individual variability in cognition,
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TABLE 1 | Examples of potential determinants of the inter-individual variability in
cognitive decline.
Determinant Mechanisms Example
Gender
Age
Education
Intelligence coefficient
Development of expertise in
a particular domain through
training
Bilingualism
Socioeconomic factors
Occupational attainment
Cognitive and social
engagement
Physical activity
Diet
Alcohol abuse
Comorbidities
Smoking
Stress
Genetic factors
Reserve Education improves neuronal
resources during childhood and
adulthood and ameliorate
age-related cognitive decline in
later adulthood. This beneficial
effect may be partly mediated by
the effects of education on
health, stress, lifestyle and
profession.
Maintenance Regular physical activity and
exercise promotes neurogenesis
and beneficial vascular changes
which enhance brain
maintenance.
contributing to the degree of response to an intervention. For
this reason, wherever possible, all these determinants should be
measured when performing a clinical study.
The progress of AD from healthy aging to SCD, MCI and
Alzheimer’s dementia is an example of poor brain maintenance
and it is modulated by reserve and compensation (57, 60, 68, 69).
Adults with higher scores on reserve proxies (e.g., education
or cognitive engagement) have less Aβ plaques, an accepted
biomarker of AD (67, 70). Also, in adults with Aβ biomarkers,
higher scores on reserve proxies are associated with a lower risk
of progression from normal cognition to the onset of clinical
symptoms (71).
In the absence of disease course-modifying treatments for
AD, prevention is an emerging approach. A large number of
modifiable AD risk factors have been identified in observational
studies, ranging from environmental ones (e.g., air pollution)
(72, 73) to lifestyle protective factors (e.g., physical activity and
the Mediterranean diet) (74–78). Diet-related disorders (e.g.,
diabetes mellitus, obesity, metabolic syndrome, hypertension,
and hypercholesterolemia) represent a considerable fraction
of such modifiable risk factors (8). Therefore, nutrition
interventions have the potential to reduce the incidence, delay the
onset, and slow down the progression and severity of dementia in
a cost-effective manner.
Role of Phenolic Compounds, n-3 PUFAs
and Vitamins in Cognitive Function
It is well-known nowadays that certain nutrients such as phenolic
compounds, omega-3 polyunsaturated fatty acids (n-3 PUFAs),
and vitamins, play a key role in the aging brain, possibly leading
to better cognitive and motor capacity (79). These compounds
are potent antioxidants and anti-inflammatory agents and are
directly involved in signaling pathways that support brain
plasticity (79).
Phenolic compounds are the secondary metabolites of plants
found in a wide range of foods, particularly in red wine, olive
oil, green tea, and blueberries (80). In both in vitro and in
vivo models, phenolic compounds directly regulate amyloidosis,
neuroinflammation, and tau aggregation (80–84). Several clinical
trials have observed the positive cognitive effects of phenolic
supplementation in cognitively healthy older adults (85–91) and
those presenting mild to moderate dementia (92–97). Other
trials, however, have failed to demonstrate these beneficial effects
in the elderly (98–103). The poor bioavailability of phenolic
compounds, difficulties in crossing the blood-brain barrier, the
heterogeneity of the phenol dosage, and quality of the study
design are several explanations for the lack of expected beneficial
outcomes from clinical trials (10, 104, 105). Besides, inter-
individual differences in the metabolism and bioavailability
of these compounds can lead to different outcomes. For
example, it is known that microbiota plays an important
role in the gut bioactivation of certain phenolic compounds
(106). Evidence is scarce, but some studies have associated
specific microbiota composition with distinct enterolignan
production (107) and with different clinical response to capsaicin
supplementation (108).
n-3 PUFAs are structural components of cell membranes that
act by displacing cholesterol from the cell membranes. Their
function is crucial in maintaining cell integrity and achieving
proper cognitive functioning (109). Among the n-3 PUFAs,
particular attention has been focused on eicosapentaenoic acid
and docosahexaenoic acid from oily fish, and its precursor alpha-
linoleic acid from nuts. These n-3 PUFAs cannot be efficiently
synthesized by human enzymes and are considered semi-
essentials, relying almost exclusively on dietary intake (105).
In AD animal models, long-term n-3 PUFAs supplementation
has been shown to improve cognition and reduce the amount
of deposited beta-amyloid (110, 111). Recently, the European
Food Safety Authority has approved a claim on “docosahexaenoic
acid and improvement of memory function” (112). However,
inconsistent results have been obtained from clinical studies with
fish oil supplementation in healthy older adults (113–118) and
in patients presenting mild to moderate AD (119–123). One
meta-analysis of ten RCTs suggested a protective effect of n-3
PUFAs within specific cognitive domains in patients with milder
forms of cognitive impairment, but no effect was observed in
healthy or AD subjects (124). In addition, a recent Cochrane
review has concluded that n-3 PUFA supplementation cannot
affect AD progression when the disease is already established
(125). Future RCTs need to clearly define the optimal n-3
PUFA status for the aging brain, and the specific population
that might benefit the most from n-3 PUFA supplements (79).
The n-3 long chain PUFA biosynthetic pathway presents high
inter-individual variability on their efficiency and is subjected
to a high genetic diversity. This variability can explain inter-
individual differences in the fate of n-3 supplementation and
the n-3 daily requirements. As an example, fatty acid desaturase
(FADS) regulates a key step on PUFA biosynthetic pathway.
Polymorphisms in this enzyme trigger different plasmatic n-3
PUFA proportions in response to an alpha-linoleic acid enriched
diet (126).
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The role of vitamins on cognitive health has also been
extensively studied although there is still a lack of clear
conclusions (127). Optimal vitamin status is essential for
the correct brain development and function. Deficiencies in
several classes of vitamins have been associated with cognitive
impairment and higher risk of dementia (128). In the case
of vitamin D, the Endocrine Society recommends keeping
vitamin D3 concentrations above 75 nmol/L (129). Several
intervention studies have addressed the effects of vitamin D3
supplementation on cognition (130–133) with limited positive
results (133). Among the vitamin B group, B12, B9 (folic acid),
and B6 are involved in homocysteine metabolism, preventing
the homocysteine-stimulation of oxidative stress (134) and
their deficiency has been associated with cognitive impairment
(135). Moreover, some promising results have supported vitamin
B supplementation with respect to cognitive function (136),
although there is as yet not enough evidence fromRCTs to sustain
its beneficial effect (137). Concerning vitamin C, MCI and AD
patients present lower levels of ascorbic acid in plasma (138, 139).
Long-term supplementation with vitamin C, however, has not
been shown to be protective against developing AD (140). On the
other hand, the supplementation of alpha-tocopherol, the most
abundant class of vitamin E in the diet, and which plays a critical
role in the protection of cell membranes from peroxidation, (141)
has revealed some clinical evidence of potential benefit (142).
Nevertheless, more trials are needed to confirm such results
(143). Finally, β-carotene (provitamin A) presents anti-amyloid
properties in vitro, but its effects in the aging population needs to
be further studied (144).
Several clinical trials have addressed the question of whether
multi-nutrient supplementation could have an impact on
cognitive function. Fortasyn Connect is a patented mix of
nutrients that act as precursors and cofactors of neuronal
membrane formation. In animal models, it has been described
as increasing synaptic function and formation (145, 146).
However, a 24-month, double-blind RCT testing the efficacy of
Souvenaid, a medical drink that contains Fortasyn Connect, has
not been capable of showing an improve in cognitive function
in individuals with prodromal AD (147). Nevertheless, in the
same RCT with less impaired subjects, promising results were
observed with respect to cognitive performance, which further
support interest in investigating nutritional interventions
in pre-clinical stages of dementia. Other nutraceutical
formulations of phenolic compounds, vitamins, and n-3
PUFA have not shown a positive impact on global cognitive
function in MCI, AD patients, and cognitively healthy older
adults (148–150).
Special precaution should be exercised when analyzing
the effects of food additives or supplements on a subject’s
cognition. Creating false expectations among consumers, as well
as unexpected safety problems, should be avoided since the
marketing of such products requires very little efficacy and
safety evidence (19). Nutrient supplementations in nutraceutical
doses may have an opposite effect compared to the nutrients
provided in dietary doses. For example, a Cochrane review
concluded that the antioxidants vitamin E and vitamin A,
taken as supplements, increased mortality in healthy participants
and patients with various diseases (151). Therefore, caution
should be taken before recommending high-dose supplements
of nutrients.
Mediterranean Diet and Cognitive Function
Over the past years, the main focus of research in nutrition
has shifted from the study of individual nutrients or single
foods to the study of complete dietary patterns which better
reflect the whole diet of a population (152). The Mediterranean
diet (MeDiet) is a healthy dietary pattern characterized by
a high intake of vegetables, fruit, legumes, olive oil, fish,
cereals, and nuts, along with moderate red wine consumption
during meals (153, 154). These components make MeDiet
rich in phenolic compounds, n-3 PUFA, and vitamins that,
in conjunction, may contribute to a better neurovascular
health, and reduced oxidative stress and chronic inflammation
(7, 155). Multiple reviews and meta-analyses of observational
studies have underlined the strong association between the
traditional MeDiet and improved cognitive function, and
reduced risk of cognitive decline and dementia, delayed AD
onset, and lower mortality in AD patients (7, 156–158). Further
valuable evidence of the effects of MeDiet on cognition comes
from the PREDIMED study, a RCT designed to test the
cardiovascular effects of MeDiet among older adults at high
cardiovascular risk (159). Volunteers who followed a MeDiet
enriched with extra virgin olive oil or nuts for up to seven
years (median of 4.8 years) were compared with a control
group who followed a low-fat diet. Those adhering to a MeDiet
for more than 4 years presented lower incidence of stroke
(159) and an improved cognitive function (160, 161). Several
mechanisms could explain the positive effects of MeDiet on
cognitive function. Basically, a reduction of the risk factors
that have independently been associated with increased risk of
dementia (162).
Due to differences in food production, food availability,
and cultural habits, a strict MeDiet cannot be extrapolated to
all non-Mediterranean countries. Therefore, besides MeDiet,
alternative healthy-dietary patterns have also been associated
with better cognitive function and reduced risk of cognitive
impairment. The blood pressure lowering DASH diet (Dietary
Approach to Systolic Hypertension) was targeted exclusively
to lower blood pressure in hypertensive and pre-hypertensive
patients. Long-term adherence to the DASH diet (6 years)
promoted the maintenance of global cognition and verbal
memory in older adults (163). On the other hand, the
MIND diet score (Mediterranean-DASH diet Intervention
for Neurodegeneration Delay) represents a modified version
of MeDiet that captures additional foods and nutrients of
DASH diet (e.g., berries or green leafy vegetables) (164).
In adjusted models, adherence to the MIND diet slowed
cognitive decline (165) and decreased AD risk (166). Finally,
the Nordic diet, followed in Scandinavian countries, is a
diet rich in phenolic compounds, unsaturated fatty acids,
and whole grain products. An observational study concluded
that adherence to the Nordic diet was associated with a
better cognitive performance in older adults with normal
cognition (167).
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Multidomain Lifestyle Interventions
Multidomain lifestyle interventions deal with multiple
modifiable risk factors of dementia simultaneously, including
nutrition, cognitive training, social support, physical activity,
and the management of the vascular risk factors (Table 2) (177).
These interventions are mainly justified by the heterogeneous
etiology and pathogenesis of dementia, including the numerous
pathways and domains involved in cognitive performance that
may be affected in the brain degeneration process (9, 177). The
promotion of adequate brain stimulation through cognitive
training and social support is thought to be useful to build
new neuronal pathways and retain the remaining ones
(177). This, in turn, increases cognitive reserve, defined as
the capacity to perform cognitive tasks properly despite
neuropathological damage to the brain (178, 179). Another key
point of multidomain interventions is caring for nutritional
status, as has been previously mentioned, the lack of specific
nutrients affects brain degeneration and some dietary patterns
are associated with better cognitive performance (177). Finally,
adequate blood flow is important in preventing cognitive decline
and also facilitates the efficient Aβ clearance from the brain
(180). Therefore, physical activity or medications that promote
cerebrovascular health are frequently included in multidomain
interventions, as they may be helpful even when dementia is
already established (177, 181, 182).
Up to the present, several studies have employed a
multidomain lifestyle approach to prevent cognitive decline,
dementia, and AD. (Table 2) (168–170, 172–174). In the Finnish
Geriatric Intervention Study to Prevent Cognitive Impairment
and Disability (FINGER), 1,260 older adults at risk of
cardiovascular disease and dementia were included. Participants
were randomized to receive a regular health advice or a 2-year
lifestyle multidomain intervention which included nutritional
guidance, group and individual physical activity, cognitive
training, and intensive monitoring of vascular and metabolic risk
factors (183). The primary outcome of cognitive performance
was measured using the Neuropsychological Test Battery (NTB)
total score (168). NTB total score was statistically higher in the
intervention group, hence, the multidomain intervention was
able to improve global cognition (168). One of the key factors
of the FINGER success was thought to be the combination
of group and individualized activities, which increased both
personal and within-group motivation and enhanced lifestyle
changes (6).
Nonetheless, the two other large, long-term, multidomain,
lifestyle-based studies failed to obtain successful results. The
Prevention of Dementia by Intensive Vascular Care Trial
(PreDIVA) targeted vascular risk factors to prevent the incidence
of dementia in 3500 cognitively healthy older adults (169).
Despite no statistically significant effects of the intervention in
the whole group (hazard ratio was 0.92, 95% CI 0.71–1.19; p
= 0.54), certain benefits on dementia incidence were found in
at-risk subgroups (169). On the other hand, the Multidomain
Alzheimer Preventive Trial (MAPT) included a 3-year n-3
PUFA supplementation (DHA+ EPA) combined with a lifestyle
intervention in order to prevent cognitive decline in 1,680
older adults with subjective memory complaints (170). Likewise,
only the individuals presenting a higher degree of cognitive
impairment benefited from the intervention (170). Findings from
these studies suggest that interventions should be specific for risk
profiles (6, 184, 185).
PERSONALIZED NUTRITION
Personalized nutrition is based on the idea that individuals
respond differently to dietary components as a result of the
interplay between environmental, social, metabolic, and genetic
factors. Targeting these variations can have an impact on final
health status. Personalized nutrition provides tailored advice
adapted to the individual’s unique characteristics with the aim of
promoting a sustainable change beneficial for health. The basis of
personalization has not yet been established. It can be established
with biological data such as genotype/phenotype, or with a more
behavioral approach, including preferences and socioeconomic
determinants such as gender, cultural aspects, and access to food
(33). Some authors have suggested “a shared decision-making
approach” as a tool for personalizing dietary advices and thus
increasing acceptance and adherence (33).
The study conducted by Zeevi et al. (186) represents a
proof-of-concept for the feasibility of personalized nutrition.
They developed a machine-learning algorithm integrating blood
parameters, anthropometric measures, gut microbiome data,
and dietary and lifestyle information, in order to predict an
individual’s postprandial glycemic response. They validated
the algorithm in an independent cohort and demonstrated
that a dietary intervention based on their prediction lowered
postprandial responses. Another study worth highlighting is
Food4Me which is, to date, the largest RCT in personalized
nutrition (187). It demonstrated that personalized nutrition was
more effective than standard population advice in relation to
dietary behavior. Personalization was based on weight, physical
activity, and dietary intake. Interestingly, the inclusion of
phenotypic/genotypic data to define the recommendation did
not produce additional benefits (187–189). Experts in the field
of nutritional genetics and genomics agree that more research
is needed to implement such approaches within the scope of
evidence-based nutrition (190, 191).
Nevertheless, no personalized nutritional study has been
carried out with the aim of improving cognitive function,
slowing cognitive decline, or reducing dementia incidence. The
implementation of personalized nutrition in clinical trials faces
a considerable number of practical, logistical, and financial
challenges. As stated by the epidemiologist Geoffrey Rose,
personal lifestyle is socially conditioned, which means that
individuals are unlikely to eat very differently from the rest
of their families and social circle. Current personalized clinical
and preventive nutritional approaches are more designed to
help individuals rather than entire populations. The challenge
for research will be to define efficient personalization methods
for increasing the impact of lifestyle interventions on the
global burden of dementia and cognitive decline, as well
as reducing health disparities when implemented on a large
scale (33).
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TABLE 2 | RCTs of multidomain lifestyle interventions for prevention of cognitive impairment, Alzheimer’s disease, and dementia.
Study (Ref)
location
N Inclusion criteria Multidomain intervention Control Duration Primary outcome Results (if available)
FINGER (168)
Finland
1,260 Cognitive performance at mean level or
slightly lower than expected for age 60–75
(CAIDE dementia risk score ≥6)
60–77 years
(i) nutritional guidance
(ii) physical exercise
(iii) cognitive training and social
activity
(iv) management of metabolic and
vascular risk factors
General health advice 2 years + 5 years
follow up
Change in cognitive
function (NTB)
Significantly positive
effects
preDIVA (169)
Netherlands
3,526 Unselected population of older people
without dementia in general practices
70–78 years
(i) nutritional advice
(ii) physical activity advice
(iii) vascular care and medical
treatment of risk factors
Usual care 6 years Cumulative incidence
of dementia and
disability score (ALDS)
No significant effects
MAPT (170)
France
1,680 Spontaneous memory complaint (MMSE
>24), with frailty (limitation in one
instrumental activity of daily living and slow
walking speed)
≥70 years
(i) nutritional advice
(ii) physical activity advice
(iii) cognitive training
(iv) vascular care
(v) and/or 800mg DHA/day
Placebo 3 years + 2 years
follow up
Change in cognitive
function (G and B)
No significant effects
Lam et al. (171)
Hong Kong
555 MCI
≥ 60 years
(i) physical exercise
(ii) cognitive activity
Social activity or only
cognitive activity or only
physical exercise
1 year Change in cognitive
function (CDR-SOB)
No significant effects
HATICE (172)
Netherlands,
Finland, France
2,600 healthy cognitive status (MMSE ≥24), with
cardiovascular risk factors
≥65 years
Interactive internet platform that
stimulates self-management of
vascular and life-style related risk
factors, with remote support
Static internet platform with
basic health info
1.5 years Composite score
based on the average
z-score of the
difference between
baseline and 18m
follow up values of BP,
LDL, and BMI
N/A
SYNERGIC (173)
Canada
200 MCI 60–85 years (i) exercise
(ii) cognitive training
(iii) vitamin D
BAT, control cognitive
training, placebo D
20 weeks + 6
month follow-up
Change in cognitive
function (ADAS-Cog 13
and plus)
N/A
LIILAC (174)
Australia
148 Healthy cognitive status (MMSE >24)
60–90 years
(i) MeDiet
(ii) exercise
Usual care or only MeDiet or
only exercise
6 months Change in cognitive
function (SUCCAB)
N/A
Daly et al. (175)
Australia
152 Healthy cognitive status (SPMSQ ≤ 2)
≥65 years
(i) progressive resistance training
(ii) lean red meat
(iii) vitamin D
Control resistance training,
advice to consume
carbohydrates and vitamin
D
6 months + 6
month follow up
Change in cognitive
function (CogState
Battery)
N/A
Rovner et al.
(176)
USA
200 African Americans with MCI
≥ 65 years
Behavior activation therapy to help
subjects develop strategies to
maintain cognitive, social and
physical activities
Supportive therapy 2 years Change in episodic
memory (HVLT-R)
N/A
FINGER, Finnish Geriatric Intervention Study; MAPT, Multidomain Alzheimer Prevention Study to Prevent Cognitive Impairment and Disability; preDIVA, Prevention of Dementia by Intensive Vascular Care; HATICE, Healthy Aging Through
Internet Counseling in the Elderly; SYNERGIC, Synchronizing Exercises, Remedies in Gait and Cognition; LIILAC, Lifestyle Intervention in Independent Living Aged Care; ADAS-Cog, Alzheimer Disease Assessment Scale Cognitive 13 and
the plus modality; ALDS, Academic Medical Center Linear Disability Score; BAT, balance and toning exercise; BMI, body mass index; BP, systolic blood pressure; CDR-SOB, Clinical Dementia Rating sum of boxes; CogState Battery,
CogState Brief Battery computerized tests; G and B, Grober and Buschke; HVLT-R, Hopkins Verbal Learning Test-Revised; LDL, low-density-lipoprotein; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; N/A, not
available; NTB, Neuropsychological Test Battery; SPMSQ, Short Portable Mental Status Questionnaire; SUCCAB, Swinburne University Computerized Cognitive Assessment Battery.
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TABLE 3 | Challenges of traditional clinical trials testing the efficacy of nutritional
interventions for dementia prevention.
Main challenges Risks or consequences
Study Design
Blinding
Adherence to the intervention
Control group contamination
Poor sustainability of the
proposed intervention
Dropout rates Decreased statistical power
Confounding and selection biases
post-baseline
Dietary assessment Misreporting and underreporting concerns
due to memory difficulties of participants
experiencing cognitive decline
Participant and researcher burden
Cognition as an outcome
Short interventions Incapacity to assess effects on primary
outcomes (e.g., dementia incidence)
Limited clinical relevance of minor
cognitive changes
Cognitive assessment tools Poor sensitivity of cognitive tests to detect
subtle changes in cognition
Target population
Heterogeneity of target
population
Inconclusive results
Healthy subsample of the
target population
Potential effects of disclosing to
participants a high risk of developing AD
Strict inclusion/exclusion
criteria
METHODOLOGICAL CHALLENGES OF
NUTRITION TRIALS FOR DEMENTIA
PREVENTION
Despite the increasing interest in the possible relationship
between nutrition and cognitive health, evidence indicating the
preventive effectiveness of nutritional strategies remains
scarce. Encouraging results from in vitro, animal, and
epidemiological studies have not been automatically translated
into successful results in RCTs. This inconsistency has been
attributed to methodological difficulties in performing nutrition
preventive RCTs, particularly against cognitive disorders
and, more generally, age-related pathological conditions
(Table 3) (192, 193).
Study Design
Conventional parallel-group RCTs with primary clinical
endpoints represent the peak of the study design hierarchy
due to their ability to infer causality between an exposure
and an outcome. They represent the main basis for medical
guidelines and health policies (194). Double blind RCTs
minimize confounding and selection biases at baseline through
randomizing the allocation of exposure (195), which is a major
challenge in observational studies. Therefore, through RCTs
it is theoretically possible to carry out a pure comparison
between intervention and control arms (195). Although they
are a fundamental design in drug efficacy study paradigms,
traditional RCTs may not be easily extrapolated to the nutritional
field (196).
One major drawback in nutritional clinical studies is that
blinding a dietary intervention is not always possible. As a
result, the adherence and effect of the intervention can be
affected by the possible knowledge of the treatment assignment
(195–197). Moreover, dropout rates are usually higher in RCT
nutritional interventions compared to drug trials, particularly
if the intervention is very demanding or is carried out during
a long time period (196). This consequently reduces statistical
power and, if a selective dropout occurs between groups, it can
lead to confounding and selection biases post-baseline (196).
Furthermore, adherence to the assigned intervention is difficult
to achieve (and assess) in nutritional trials of long duration or
when the assigned intervention substantially differs from the
participant’s usual diet (194, 196, 197). Such constraints not
only affect the study results, but also call into question the
sustainability of dietary interventions.
For ethical and methodological reasons, the control group
of nutritional RCTs is not typically placebo-controlled, but
instead it is often a low-dose group, which can cause poor
contrasts among groups (196). In addition, before entering the
study, all participants are informed about the potential effects
of the intervention. Therefore, there is always the possibility
that control subjects look for dietary components that mimic
the intervention (195). All these limitations regarding the choice
of the control group can mask the true effect of a nutritional
intervention (196).
Traditional Dietary Assessment
Accurate dietary assessment is one of the main challenges
researchers face when performing nutritional studies. The
complexity of measuring diet is increased by the constant
introduction of new products and trends which have an impact
on consumers’ decisions (198). This issue has worse perspectives
when dealing with older people. The elderly make up a very
heterogeneous group, with a wide range of ages, health and
physical status, cognitive situation, and socioeconomic level.
Aging is associated with several changes that can affect directly
or indirectly dietary intake and nutritional status. There is a loss
of smell and taste, difficulties in chewing and swallowing, and
changes in living conditions that can all have an impact on dietary
intake (199).
Food frequency questionnaires (FFQ), food diaries, and 24-h
dietary recalls are the three main traditional methods of dietary
assessment. The 7-day weighed food record is the technique that
canmost capture details and variation in the diet compared to the
FFQ or 24-h dietary recall (200). However, prolonged recording
of 7-day weighed food records has been linked tomis- and under-
reporting as it may be too demanding for the participant, and
changes in normal behavior and dietary habits (201). The goal of
dietary assessment is to achieve a balance between the collection
of reliable and accurate data, and the burden for the patient
and researcher. In order to do so, the National Cancer Institute
has standardized an automated web-based self-administered 24-
h recall tool, ASA24. A study has shown that self-administration
of at least 3 ASA24 on separate days provided equivalent results to
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a 4-day food diary. This represented a cost-benefit improvement
in terms of data collection and management (202). Nevertheless,
methods based on self-reporting data are prone to substantial
misreporting. They challenge the participant’s memory and
capacity to estimate food content and portion size (203) which
become even less reliable when participants present cognitive
decline. The tendency to under-report in dietary assessment
has been not only associated with body weight and BMI, but
also with gender, sociodemographics, lifestyle, education, and
diet characteristics. It has been reported that the elderly tend
to under-report in 24-h dietary recalls due memory difficulties
and cognitive loss (203). Traditional dietary assessment methods
are currently being re-defined with the development of new
technological tools such as m-health, machine learning, and food
image recognition models. Simultaneously, the rise of the ‘omics
techniques has enabled the development of new biomarkers
capable of assessing dietary exposure.
Cognitive Outcomes
The choice of the method used to assess cognitive performance is
crucial to obtain successful results. Primary cognitive outcomes
should be unambiguous and clinically relevant, such as reducing
the incidence of dementia or delaying its onset. Nevertheless,
such objectives require large sample sizes with long-term
follow-ups when intervening at the age of 60–70 or earlier
(192). Short-term preventive interventions are usually unable to
evaluate the intervention effects on “hard outcomes.” Instead,
they measure cognitive function by means of a composite
score that includes a battery of validated cognitive tests
administered at discrete intervals. Although cognitive change is
an indicator of progression across the disease continuum, the
clinical importance of the observed cognitive changes remains
unclear (193). In addition, the sensitivity of cognitive tests to
detect subtle individual cognitive changes due to nutritional
interventions in the earliest stages of dementia has been
questioned. There is no consensus about the gold standard tool to
measure cognitive decline (204). Experts recommend including
functional measures, health-related quality of life, health care
utilization, and institutionalization as outcomes for dementia
preventive trials.
Target Population
Defining the ideal target population is challenging due to the
nature of the development and progression of dementia, as there
is a delay between risk exposure, disease onset, and clinical
manifestation (192). The optimal age for preventive trials is
still unknown: Acting prematurely in the natural history of the
disease would require a too long a follow-up to be realistic, while
intervening too late might result in too little efficacy (192). The
current target population groups for preventive trials are usually
cognitively intact individuals or those presenting SCD/MCI.
Such groups are largely heterogeneous and the probability
of short-term changes in cognition is low. Consequently, there
is the need to increase sample size, length of intervention,
and, as a consequence, human and financial resources (49). In
order to homogenize study samples, the presence of several
biomarkers of cognitive decline is usually reflected in the
inclusion criteria, while having comorbidities or poor levels
of education are part of the exclusion criteria. However, the
disclosure of biomarker positivity among study participants
carries potential risks for the individual, including fear or
anxiety about the future, which can influence the subsequent
neuropsychological testing or perception of clinical decline (205).
In addition, compared to pharmacological trials, the use of an
extensive inclusion/exclusion criteria is not particularly relevant
in nutrition interventions, as contraindications are not a primary
concern (49). Strict inclusion/exclusion criteria merely lead to a
healthier subsample of the target population (49).
Given the limitations of traditional RCTs, many researchers
are expressing the need for novel patient-centered experimental
designs such as N-of-1 trials, in order to achieve individualized,
targeted treatments, and recommendations for clinical care (8,
195, 206, 207).
N-OF-1 CLINICAL TRIALS
Rationale
Dementia and AD are characterized by a wide heterogeneity in
terms of risk factors and clinical manifestation and progression.
Such heterogeneity has been recognized as a critical issue in the
current approach to implement preventive strategies and develop
new therapies (208). For example, genetics account for more
than 50% of the phenotypic variance of late-onset AD (209), and
there are gender differences in the phenotype and progression
of AD (208). Nutritional interventions also encompass large
heterogeneity among individuals because environmental, social,
metabolic, and genetic factors influence response to dietary
interventions. According to the principle of equifinality, the
earlier the disease process is, the higher the inter-individual
variability. Therefore, it is essential to explore the heterogeneity
involved in nutritional interventions directed toward improving
cognitive function in order to achieve the final goal of being able
to make individual-based treatment decisions.
Nevertheless, evidence from traditional clinical trials is
probabilistic and there is no certainty of individual benefit
(33). This is because parallel-group RCTs estimate the average
treatment effect of the studied intervention, since randomization
theoretically ensures overall comparability among treatment
groups. The absence of differences in baseline characteristics
among study groups does not exclude the possibility that
some individuals respond or benefit to a greater or lesser
degree than the reported average. This is referred to as
heterogeneity of treatment effects (HTE) (210) which can
be attributed to treatment, patient, or environmental factors,
and it is usually presented as considerable variations around
group means. Examining the HTE is central to patient-centered
outcome research and for informing personalized treatment
decisions (211).
The most common approaches to exploring HTE in clinical
trials are subgroup analyses, the stratification of patients
according to risk profiles, and meta-analysis (18, 210). Subgroup
analyses are typically performed to detect characteristics among
the study population that are associated with a greater benefit
from the intervention, no benefit, and even with harm (212).
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Nevertheless, subgroup analyses may not be able to detect
clinically significant differences in treatment effects among
participants when multiple factors determine the risk (213).
One alternative is to consider risk-stratified analyses. Participant
stratification, using a multivariate risk model, makes it possible
to compare the treatment effect across a broader range of risk
factors or patient attributes than a conventional one-variable-at-
a-time subgroup analysis (213). Nevertheless, such stratification
is not always feasible in RCTs that target dementia or AD, since
the available biomarkers only detect the presence of the disease,
but not its onset and progression. In addition, although some
risk scores exist (214, 215), there is a limited understanding
of the interplay among individual dementia risk factors during
the life course, and how they affect the pathophysiology of
the disease and impact on the brain health (216). Finally,
regarding meta-analysis, it is difficult to pool multiple RCTs
due to differences in the diagnostic procedure and criteria
for dementia and AD, as well as variations in the measures
used, anticipated outcomes, and study design. N-of-1 trials can
overcome the difficulties of parallel group RCTs in determining
HTE as they focus on individuals in order to establish their
optimal treatment.
Design and Indications
The design of an N-of-1 clinical trial is determined by the
research question to be answered, in other words, by the nature
of the intervention and the characteristics of the outcome to be
measured. In the case of nutritional studies, the intervention can
range from a single-compound intervention to a complete change
of dietary pattern or a multidomain intervention. The first group
of studies could adopt a more pharmacological N-of-1 approach
whereas the second group of interventions would require a more
complex study design including behavioral changes, learning,
and habituation periods.
Traditional N-of-1 Approach
To perform a traditional N-of-1 design, several assumptionsmust
be met. First, it is indicated when there is uncertainty regarding
the comparative effectiveness of an individual’s treatment, and
when significant individual differences in intervention response
are expected (20, 217). Second, the study disease must be chronic,
stable, or slowly progressing, with evaluable symptoms or valid
biomarkers to allow monitoring during the course of the study
(20, 217). Finally, interventions must be reversible, have rapid
efficacy and minimal carryover, tolerate wash-out periods (if
necessary), and multiple-crossovers (20, 217).
In the case of a single-compound, nutritional intervention, a
traditional N-of-1 approach can be followed as in drug efficacy N-
of-1 studies. The participant undergoes two or more nutritional
interventions in a random order (e.g., A-B-A, A-B-A-B, or A-B-
A-C-A-D), and this process may be repeated several times (in
series of N-of-1 trials) (17). Therefore, the individual treatment
effects can be re-estimated after each intervention period.
The number of time-series conducted can be pre-specified or
adapted in order to stop the trial when there is reasonable
statistical certainty to identify the most effective treatment for the
participant (18). The aggregation of data from series of N-of-1
trials allows the possibility of controlling for random or patient
fixed effects, as well as covariates, sequence or center effects (18).
Ultimately, this design enables the identification of individuals
who share a response profile tackling the similarities between
them (206, 218). Thus, this single-person, multiple crossover,
randomized trial design is able to provide direct and objective
evidence about the value of a particular single-compound or
nutritional intervention for the patient, and also for the general
population (217).
An example of this traditional N-of-1 approach is the recently
started Personalized Research on Diet in Ulcerative Colitis
and Crohn’s Disease (PRODUCE) trial (NCT03301311). Using
series of N-of-1 trials, patients will cross-alternate between two
different carbohydrate diets in order to determine their effects in
reducing symptoms and inflammatory burden at both individual
and population level.
Modified N-of-1 Design for Studying Cognitive
Decline Preventive Interventions
In the field of dementia prevention, current evidence points
towards multidomain interventions addressed to individuals
at high risk. These types of interventions imply behavioral
changes that are difficult to reverse, so it is hard to imagine the
possibility of conducting multiple crossovers in a single person.
In addition, cognitive outcomes are not susceptible to short-
term changes and there are not currently sensitive biomarkers of
disease progression.
Our proposal is a modified N-of-1 approach, which would
start with a “baseline phase A” where a participant would
undergo through an extensive evaluation of his or her lifestyle
habits, socioeconomic status, medical history, and laboratory
and cognitive assessments (219). Baseline data should appear
stable before the implementation of the intervention in order
to ensure that cognitive function changes when, and only
when, the multidomain intervention is introduced for all
participants. During “intervention phase B,” researchers would
repeatedly assess adherence to the targeted behavior and the
evolution of participant’s cognitive status, making use of the
latest technological devices for recording continuous health data
(Figure 3).
As the intervention effect estimation is based on comparisons
between the intervention phase B and the baseline phase A,
the estimation is susceptible to bias when events other than
intervention cause shifts in the time-series (220). In these
occasions, the assurance of the stability of the baseline period
is crucial. Moreover, the use of a multiple baseline design
can improve the accuracy of the baseline phase by raising
awareness among researchers about the presence of potential
threats to internal validity (220). In the case of AB study
designs, the combination of several AB experiments in multiple
subjects and the addition of multiple-baseline increases the
power of the observations (221). In such cases, the length of
the baseline period varies systematically and is randomized
for each participant. As exemplified in Figure 3, participant
1 would start the multidomain intervention after 1 baseline
month, another after 1.5 baseline months, then 2, and so
on. The staggered introduction of the intervention allows for
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FIGURE 3 | (A) Individual-level analysis of the intervention effect in N-of-1
nutritional studies directed at improving cognitive function. Baseline
observational phase A duration is randomized among volunteers. Multimodal
intervention phase B triggers a different response to each individual.
(B) Population-level analysis of the intervention effect. Individuals are
aggregated according to their response. High respondents and moderate
respondents improved their cognitive performance following the intervention.
Low respondents maintained cognitive performance with the intervention.
Finally, cognitive decline progressed in non-respondents despite the
intervention.
separation of intervention effects from those of maturation,
experience, learning, and practice (220, 222). Consequently,
multiple baseline designs are strongly recommended in single-
case intervention studies when reversal designs are not
feasible (221).
Concerning the statistical analysis, it is recommended to, first,
perform a visual analysis (e.g., by means of a spaghetti plot)
in order to determine whether there is a functional relation
between the intervention and the outcome. The visual analysis
includes the evaluation of the level (mean score of the data within
a phase), the trend (the slope of the best-fitting straight line
for the data within phase), and the variability (the fluctuation
of the data around the mean) (222). If there is a potential
functional relationship between intervention and outcome, a
second step is to perform a quantitative analysis, firstly at the
individual level and secondly at the population level (between-
subjects). As there is not a consensus about which quantitative
methods are more appropriate, some authors recommend to
conduct a sensitivity analysis and to report multiple effect size
estimators (222). If there is consistency across different effect
size estimators, there is stronger evidence for the efficacy of the
intervention (222).
Therefore, the aggregation of data from multiple N-of-1 trials
studying the same lifestyle interventions could be used to explore
trends in data that may reveal the characteristics of participants
responding to the intervention, as well as confounding factors
that could be incorporated into the analysis of the intervention
effects and future trials (207). The meta-analysis of multiple N-
of-1 trials would therefore take advantage of the continuous and
intensive follow-up of participants. It could thus be possible to
obtain sufficiently detailed information from each participant to
achieve a high level of evidence of the intervention effects for both
the individual and the population.
Second Step N-of-1 Studies
The proposed N-of-1 study approach could also be applied as
a second step in the analysis of large concluded intervention
studies (e.g., FINGER, preDIVA, or MAPT). This would allow
the examination of the size of the intervention effect at
an individual level. This approach would enable sub-group
identification of treatment respondents and non-respondents
and the classification of factors that could be influencing
treatment response and treatment adherence. Furthermore,
the sub-group data aggregation would allow the accurate
analysis of biomarker trends and changes within the study to
better understand the disease progression within sub-groups.
Nevertheless, to do so, N-of-1 assumptions would need to be
met before performing the analysis. Firstly, to have performed
a continuous monitoring of the volunteers’ treatment adherence
and response to be able to detect and predict changes in
treatment responses. Secondly, a complete characterization of
the volunteers is needed to understand the heterogeneity of the
obtained results. Lastly, the stability of the studied condition
before treatment initiation should be ensured. In the case
that stability cannot be warranted, causality could also be
determined when changes are observed in a sub-group only in
the treatment intervention but not in the control intervention. In
this situation, the power associated to within-subject comparison
would be lost. This second step N-of-1 analysis would provide
valuable information to personalize treatment and to predict
and prevent condition evolution. This would be an exploratory
approach, and based on the acquired knowledge, it could be
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used as preliminary data to perform a confirming first step
N-of-1 trial.
Main Challenges of N-of-1 Trials
Lack of Control Group
In the proposed modified N-of-1 approach, there is no control
intervention, just a baseline phase, which is used to determine
the size of the effect. In our proposed N-of-1 study design,
determination of treatment causality would require first, a stable
baseline, and second, an observable change coinciding with the
intervention. Causal determination would be reinforced by the
replication of the results in further subjects (223). As previously
stated, the multiple baseline design and the continuous follow-
up of participants can improve the internal validity of the
results. However, the lack of a control group makes it difficult to
match non-specific effects of the intervention such as expectation
or attention.
Monitoring Behavior Over Time
In N-of-1 trials it is necessary to measure behavior over time
in order to obtain a representative picture of each participant’s
lifestyle habits. The monitoring process can itself produce
changes in behavior due to the awareness of being monitored,
which is known as participant reactivity. This can lead to
inaccurate baseline data, jeopardizing the determination of the
intervention effects (224). In addition, whilst future technology
promises high quality objective dietary and cognitivemonitoring,
current approaches still need to overcome some challenges.
Continuous diet assessment
N-of-1 nutritional studies seek a continuous and intensive
monitoring of the volunteers in order to examine dietary
choices and assess the response to specific dietary components.
At present, traditional diet assessment methods do not
enable continuous assessment, technology is thus aiming to
improve and adapt these tools. Technology-based approaches
have great potential, reducing both patient and investigator
burden, as well as decreasing economic and time investment
(198, 225, 226). For instance, image-assisted dietary assessment
tools have appeared in order to estimate energy and nutrient
intake. Several pilot studies have demonstrated that images
provide improved self-reported dietary intake by decreasing
the unreported/misreported errors. However, food image
recognition fails when there are hidden ingredients, and
cooking methods and cultural aspects that change nutritional
composition (227). Consequently, whilst image-assisted dietary
assessments improve dietary error they still need to be supported
by additional information. Likewise, special consideration needs
to be given to the use of technology-based tools for dietary
assessment in older adults as most of these approaches have been
tested with younger people. The elderly may be reticent in the
use of computer-based technology, encountering difficulties in
its management, which may lead to unreliable diet information.
Dietary biomarkers have appeared as the optimal way to
measure exposure to a certain food item or nutrient, they
however, require equipment and expertise (198). Moreover, they
may need invasive specimens such as blood or feces. Biomarkers
can change their concentrations depending on individual
characteristics including gender, absorption, metabolism,
genetics, microbiota, and environment (228).
The development of high-throughput, technology-based –
omics research, especially metabolomics, has appeared as a
new tool to assess an overall picture of dietary intake.
Food metabolomics can identify novel diet-related biomarkers
and investigate the mechanism of action behind nutritional
interventions through changes in metabolic pathways. The food
metabolome is highly complex and variable, nevertheless, it
provides a unique and rich source of information regarding an
individual’s diet (229). Inter-subject variation, and the short life of
certain metabolites which may not represent usual intakes, need
to be taken into consideration. A biomarker has to be sensitive to
intake, food specific, and easy to measure. A single measurement
of the metabolome is not sufficient to provide an overview of
a long-term dietary pattern (228). Efforts have been made in
order to identify the metabolomics fingerprint associated with
different dietary patterns, going beyond single-food or single-
nutrient biomarkers (229–231). These studies have been able to
detect and identify new biomarkers associated with food patterns
in free-living populations. Nevertheless, food metabolomics is
still at an initial stage and represents a complement rather than
a replacement of traditional diet assessment methods (232).
Continuous cognitive monitoring
Neuropsychological test batteries have high specificity and
sensitivity for the detection of the current cognitive state. They
do, however, require considerable resources and are quite time-
consuming with respect to continuously monitoring alterations
in the cognitive status during a clinical trial. New computerized
cognitive tests are being developed for longitudinal cognitive
monitoring (233). They have the potential to use random
elements and alternate sequences to minimize learning effects,
and they can adapt the testing difficulty to the baseline cognitive
performance of each individual. In addition, traditional pencil-
based or computerized self-reported cognitive tests can be
combined with real-time sampling methods in a participant’s
natural environment (e.g., ecological momentary assessment–
EMA) which could reduce retrospective reporting biases (224).
Finally, web-based platforms of cognitive stimulation games can
be used to longitudinally evaluate and monitor each participant’s
performance in specific cognitive domains.
Statistical Design and Analytic Considerations for
N-of-1 Trials
The relevance and importance of N-of-1 trials is increasing and,
as a result, there is an abundance of literature on statistical
methodology (25, 206, 234). The importance of these trials is also
reflected by the fact that the CONSORT (Consolidated Standards
of Reporting Trials) statement has been extended for these type of
studies (17). Several of the methodological challenges that N-of-1
trials encounter are the following:
• The determination of the number of observations needed for
valid inference requires a careful planning of each trial. It will
depend on the block design (i.e., the number and order of
blocks per treatment) and prior knowledge of both the within
and between-block variation. In addition, if several N-of-1
Frontiers in Nutrition | www.frontiersin.org 13 July 2019 | Volume 6 | Article 110
Soldevila-Domenech et al. N-of-1 Clinical Studies: Nutrition and Cognition
trials are planned with the purpose of pooling the results,
between-patient variance will also play a key role to determine
the number of parallel N-of-1 trials (20).
• Moreover, the computation of the number of measurements
needed has to account for the fact that the data of
N-of-1 trials have a time-series structure, which implies
autocorrelation (31).
• Variables that can be recorded constantly by means of
mobile applications, which provide individual time-series,
can be analyzed with standard statistical techniques such
as autoregressive integrated moving average (ARIMA) and
autoregressive moving average (ARMA) models. However, the
inclusion of the information of such time-series as a covariate
in a regression model is not straightforward and various
possibilities should be considered. For example, a time-series
on physical activity could be summarized by means of the
mean activity per day, the cumulative activity, or a moving
average over several days.
• Pooling the results of several N-of-1 trials can be carried
out in different ways and will depend on the data at
hand. On one hand, the results from several trials could be
jointly analyzed by means of linear mixed models or meta-
analysis (25). However, there might be substantial differences
among the patients of several N-of-1 trials and this data
heterogeneity could complicate such an analysis. Another
approach is to identify patients with similar response profiles
and subsequently study what they have in common (206). For
this purpose, graphical inspections of the resulting time series
in the case of continuously recorded variables could be used.
CONCLUSION
Advances in the field of dementia prevention require
the integration of evidence from multiple study designs,
technologies, and methodologies with complementary
strengths and weaknesses (235). We propose N-of-1 or
single person clinical trials to address some of the current
shortcomings of dementia prevention trials. They can
provide knowledge concerning individual differences in the
response to dietary interventions, which may reveal insights
of the mechanisms behind interventions. In addition, the
longitudinal personal data acquisition will increase the value
of each participant’s contribution in the trial by improving
the characterization of previously unmeasured confounders
(236). N-of-1 trials also offer the potential to evaluate and
predict intervention effects in populations that are typically
excluded from clinical trials, such as the elderly with multiple
comorbidities or individuals from low socioeconomic groups.
This approach, we believe, offers an exciting opportunity
to optimize trial efficiency and create future designs to
maximize the benefit of interventions in an equitable and
sustainable way.
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